Login Register Cart 0
Generic placeholder image

Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1573-4064
ISSN (Online): 1875-6638

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Discovery of Substituted N-(6-Chloro-3-cyano-4-phenyl-4H-chromen-2-yl)- 2-(4-chloro-phenoxy)-acetamide for Biphasic Anticancer and Anticonvulsant Activities

Author(s): Divya Chauhan*, Syad Riaz Hashim, Prinka Rani, Sushil Kumar, Navratan Shrimal, Divya Shastri and Vinit Raj*

Volume 17, Issue 3, 2021

Published on: 06 December, 2019

Page: [203 - 215] Pages: 13

DOI: 10.2174/1573406415666191206101617

Price: $65

Abstract

Background: Privileged 4H-chromenes possess potent anticancer and anticonvulsant activities. By the inspiring potency of 4H-chromenes and demands of the present era of scaffolds, an effective molecule was discovered for the treatment of cancer and related diseases.

Objective: This study designed and synthesized a novel series of 4H-chromene derivatives from one-port synthesis for the treatment of cancer and other such diseases.

Methods: A side amide chain was substituted in multiple steps on the amine group of chromene. Later, the anticancer activity of synthesized compounds was investigated against the human colon adenocarcinoma cell line (HT-29) using sulforhodamine B (SRB) assay. Moreover, anticonvulsant activity was also detected using maximal electroshock seizure (MES) model and subcutaneous Metrazol Seizure Threshold Test (scMET) in albino Wistar rats. Neurotoxicity was evaluated by using the rotarod test. Before the synthesis, docking studies were performed using various molecular targets. Subsequently, the computational study of the titled compounds was performed to predict the pharmacokinetic profile.

Results: Among the fifteen tested compounds, A4 and A9 were found to be active against HT-29 cells (growth inhibitory dose 50% (GI50) <11μM). Moreover, compounds A4 showed the protection at 300mg/kg in scMET (h) for albino Wistar rats and compounds A9, A11, and A15 exhibited the anticonvulsant effect at the doses 100, 300 and 300 mg/kg, respectively in MES screen (h).

Conclusion: Due to these encouraging results, we concluded that both A4 and A9 may be effective for treatement against colon cancer, while compound A9 may be used as a considerable effective molecule for the treatment of epilepsy.

Keywords: Anticonvulsant activity, 4H-Chromene, molecular docking, synthesis, HT-29 cells, epilepsy.

« Previous Next »
Graphical Abstract

[1]
Ellis, G.P. Chromenes, chromanones, and chromones-Introduction. Chem. Het. Comp. Chromenes Chromanones Chromones, 1977, 31, 1-10.
[2]
Thompson, C.B. Apoptosis in the pathogenesis and treatment of disease. Science, 1995, 267(5203), 1456-1462.
[http://dx.doi.org/10.1126/science.7878464] [PMID: 7878464]
[3]
Okasha, R.M.; Alblewi, F.F.; Afifi, T.H.; Naqvi, A.; Fouda, A.M.; Al-Dies, A.M.; El-Agrody, A.M. Design of new benzo[h]chromene derivatives: antitumor activities and structure-activity relationships of the 2,3-positions and fused rings at the 2,3-positions. Molecules, 2017, 22(3), 479.
[http://dx.doi.org/10.3390/molecules22030479] [PMID: 28335470]
[4]
Taylor, A.P.; Robinson, R.P.; Fobian, Y.M.; Blakemore, D.C.; Jones, L.H.; Fadeyi, O. Modern advances in heterocyclic chemistry in drug discovery. Org. Biomol. Chem., 2016, 14(28), 6611-6637.
[http://dx.doi.org/10.1039/C6OB00936K] [PMID: 27282396]
[5]
Laskar, S.; Brahmachari, G. Access to biologically relevant diverse chromene heterocycles via multicomponent reactions (MCRs): Recent advances. Org. Biomol. Chem., 2014, 2, 1-50.
[6]
Gourdeau, H.; Leblond, L.; Hamelin, B.; Desputeau, C.; Dong, K.; Kianicka, I.; Custeau, D.; Boudreau, C.; Geerts, L.; Cai, S.X.; Drewe, J.; Labrecque, D.; Kasibhatla, S.; Tseng, B. Antivascular and antitumor evaluation of 2-amino-4-(3-bromo-4,5-dimethoxy-phenyl)-3-cyano-4H-chromenes, a novel series of anticancer agents. Mol. Cancer Ther., 2004, 3(11), 1375-1384.
[PMID: 15542776]
[7]
Hegab, M.I.; Abdulla, M.M. 4-Chloro-2,2-disubstituted chromen-3-carboxaldehyde: synthesis of some fused polycyclic heterocycles as anti-inflammatory, analgesic, anticonvulsant, and antiparkinsonian agents. Arch. Pharm. (Weinheim), 2006, 339(1), 41-47.
[http://dx.doi.org/10.1002/ardp.200500124] [PMID: 16411175]
[8]
Kuarm, B.S.; Reddy, Y.T.; Madhav, J.V.; Crooks, P.A.; Rajitha, B. 3-[Benzimidazo- and 3-[benzothiadiazoleimidazo-(1,2-c)quina-zolin-5-yl]-2H-chromene-2-ones as potent antimicrobial agents. Bioorg. Med. Chem. Lett., 2011, 21(1), 524-527.
[http://dx.doi.org/10.1016/j.bmcl.2010.10.082] [PMID: 21134751]
[9]
Fernández-Bachiller, M.I.; Pérez, C.; Monjas, L.; Rademann, J.; Rodríguez-Franco, M.I. New tacrine-4-oxo-4H-chromene hybrids as multifunctional agents for the treatment of Alzheimer’s disease, with cholinergic, antioxidant, and β-amyloid-reducing properties. J. Med. Chem., 2012, 55(3), 1303-1317.
[http://dx.doi.org/10.1021/jm201460y] [PMID: 22243648]
[10]
Sashidhara, K.V.; Kumar, M.; Modukuri, R.K.; Srivastava, A.; Puri, A. Discovery and synthesis of novel substituted benzocoumarins as orally active lipid modulating agents. Bioorg. Med. Chem. Lett., 2011, 21(22), 6709-6713.
[http://dx.doi.org/10.1016/j.bmcl.2011.09.053] [PMID: 21983443]
[11]
Cai, S.X.; Drewe, J.; Kemnitzer, W. Discovery of 4-aryl-4Hchromenes as potent apoptosis inducers using a cell-and caspasebased Anti-cancer Screening Apoptosis Program (ASAP): SAR studies and the identification of novel vascular disrupting agents. Anti-Cancer Agents Med. Chem. (Formerly Curr. Med. Chem.-Anti-Cancer Agents), 2009, 9(4), 437-456.
[12]
Foroumadi, A.; Emami, S.; Sorkhi, M.; Nakhjiri, M.; Nazarian, Z.; Heydari, S.; Ardestani, S.K.; Poorrajab, F.; Shafiee, A. Chromene-based synthetic chalcones as potent antileishmanial agents: synthesis and biological activity. Chem. Biol. Drug Des., 2010, 75(6), 590-596.
[http://dx.doi.org/10.1111/j.1747-0285.2010.00959.x] [PMID: 20337782]
[13]
Lee, K.S.; Khil, L.Y.; Chae, S.H.; Kim, D.; Lee, B.H.; Hwang, G.S.; Moon, C.H.; Chang, T.S.; Moon, C.K. Effects of DK-002, a synthesized (6aS,cis)-9,10-Dimethoxy-7,11b-dihydro-indeno[2,1-c]chromene-3,6a-diol, on platelet activity. Life Sci., 2006, 78(10), 1091-1097.
[http://dx.doi.org/10.1016/j.lfs.2005.06.017] [PMID: 16153663]
[14]
Patil, S.A.; Patil, R.; Pfeffer, L.M.; Miller, D.D. Chromenes: potential new chemotherapeutic agents for cancer. Future Med. Chem., 2013, 5(14), 1647-1660.
[http://dx.doi.org/10.4155/fmc.13.126] [PMID: 24047270]
[15]
Wang, J.L.; Liu, D.; Zhang, Z.J.; Shan, S.; Han, X.; Srinivasula, S.M.; Croce, C.M.; Alnemri, E.S.; Huang, Z. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc. Natl. Acad. Sci. USA, 2000, 97(13), 7124-7129.
[http://dx.doi.org/10.1073/pnas.97.13.7124] [PMID: 10860979]
[16]
Doshi, J.M.; Tian, D.; Xing, C. Structure-activity relationship studies of ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (HA 14-1), an antagonist for antiapoptotic Bcl-2 proteins to overcome drug resistance in cancer. J. Med. Chem., 2006, 49(26), 7731-7739.
[http://dx.doi.org/10.1021/jm060968r] [PMID: 17181155]
[17]
Sudha, B.N.; Sastry, V.G.; Harika, M.S.; Yellasubbaiah, N. Synthesis of 3-(5-phenyl-1, 3, 4-oxadiazol-2-yl)-2H-chromen-2-ones as anticonvulsant agents. Indian J. Chem. Section B, 2018, 57(05), 737-745.
[18]
Angelova, V.T. AndreevaGateva, P.A.; Vassilev, N.G.; Tafradjiiska-Hadjiolova, R.; Surcheva, S.; Jana, T. Anticonvulsant activity of newly synthesized 2H-chromene based hydrazones in ICR mice. Compt. Rend. Acad. Bulg. Sci., 2016, 69, 513-520.
[19]
OECD Guidelines for the Testing of Chemicals. 2001.
[20]
Castel Branco, M.M.; Alves, G.L.; Figueiredo, I.V.; Falcão, A.; Caramona, M.M. The maximal electroshock seizure (MES) model in the preclinical assessment of potential new antiepileptic drugs. Methods Find. Exp. Clin. Pharmacol., 2009, 31, 101-106.
[21]
Stables, J.P.; Kupferberg, H.J. The NIH anticonvulsant drug development (ADD) program: preclinical anticonvulsant. Mol. Cell. Targets Antiepileptic Drugs, 1997, 12, 191.
[22]
White, H.S.; Johnson, M.; Wolf, H.H.; Kupferberg, H.J. The early identification of anticonvulsant activity: role of the maximal electroshock and subcutaneous pentylenetetrazol seizure models. Ital. J. Neurol. Sci., 1995, 16(1-2), 73-77. 73-77
[http://dx.doi.org/10.1007/BF02229077] [PMID: 7642355]
[23]
Dunham, N.W.; Miya, T.S. A note on a simple apparatus for detecting neurological deficit in rats and mice. J. Am. Pharm. Assoc., 1957, 46(3), 208-209.
[http://dx.doi.org/10.1002/jps.3030460322] [PMID: 13502156]
[24]
Vichai, V.; Kirtikara, K.; Sulforhodamine, B. Colorimetric assay for cytotoxicity screening. Nat. Protoc., 2006, 1(3), 1112-1116.
[http://dx.doi.org/10.1038/nprot.2006.179] [PMID: 17406391]
[25]
Boyd, M.R. The NCI in vitro anticancer drug discovery screen. In: Teicher B.A. Eds., Anticancer Drug Development Guide. Cancer Drug Discovery and Development; Humana Press: Totowa, NJ, 1997; pp. 23-42.
[http://dx.doi.org/10.1007/978-1-4615-8152-9_2]
[26]
De Boer, E.C.; De Jong, W.H.; Steerenberg, P.A.; Aarden, L.A.; Tetteroo, E.; De Groot, E.R.; Van der Meijden, A.P.M.; Vegt, P.D.J.; Debruyne, F.M.J.; Ruitenberg, E.J. Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer. Cancer Immunol. Immunother., 1992, 34(5), 306-312.
[http://dx.doi.org/10.1007/BF01741551] [PMID: 1540977]
[27]
Romanowski, M.J.; Scheer, J.M.; O’Brien, T.; McDowell, R.S. Crystal structures of a ligand-free and malonate-bound human caspase-1: implications for the mechanism of substrate binding. Structure, 2004, 12(8), 1361-1371.
[http://dx.doi.org/10.1016/j.str.2004.05.010] [PMID: 15296730]
[28]
Storici, P.; De Biase, D.; Bossa, F.; Bruno, S.; Mozzarelli, A.; Peneff, C.; Silverman, R.B.; Schirmer, T. Structures of γ-aminobutyric acid (GABA) aminotransferase, a pyridoxal 5′-phosphate, and [2Fe-2S] cluster-containing enzyme, complexed with γ-ethynyl-GABA and with the antiepilepsy drug vigabatrin. J. Biol. Chem., 2004, 279(1), 363-373.
[http://dx.doi.org/10.1074/jbc.M305884200] [PMID: 14534310]
[29]
Lagorce, D.; Sperandio, O.; Galons, H.; Miteva, M.A.; Villoutreix, B.O. FAF-Drugs2: free ADME/tox filtering tool to assist drug discovery and chemical biology projects. BMC Bioinformatics, 2008, 9(1), 396.
[http://dx.doi.org/10.1186/1471-2105-9-396] [PMID: 18816385]

Rights & Permissions Print Cite
Article Metrics
28
1
© 2024 Bentham Science Publishers | Privacy Policy